Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Therapeutics (TSX:GUD) to acquire regional rights to Alzheimer’s drug

Trevor Abes  April 23, 2021

Knight Therapeutics to Acquire Regional Rights to Exelon®

GlobeNewswire April 23, 2021

Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference

GlobeNewswire April 13, 2021

Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results

GlobeNewswire March 25, 2021

Notice of Knight Therapeutics' Fourth Quarter 2020 Results Conference Call

GlobeNewswire March 18, 2021

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA(TM) - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

GlobeNewswire March 1, 2021

Knight Announces Filing of Final Base Shelf Prospectus

GlobeNewswire December 23, 2020

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

Canada NewsWire December 11, 2020

Knight Announces Filing of Preliminary Base Shelf Prospectus

GlobeNewswire December 10, 2020

Knight Therapeutics Reports Third Quarter 2020 Results

GlobeNewswire November 13, 2020

Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call

GlobeNewswire November 6, 2020

Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil

GlobeNewswire October 26, 2020

Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

GlobeNewswire September 3, 2020

Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

GlobeNewswire August 25, 2020

Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership

GlobeNewswire August 14, 2020

Knight Therapeutics Reports Second Quarter 2020 Results

GlobeNewswire August 13, 2020

Notice of Knight Therapeutics' Second Quarter 2020 Results Conference Call

GlobeNewswire August 6, 2020

Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana

GlobeNewswire July 15, 2020

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 10, 2020

Knight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo Biotoscana

GlobeNewswire July 8, 2020